Search

Your search keyword '"Hammarstedt, Ann"' showing total 271 results
Start Over Author "Hammarstedt, Ann"
271 results on '"Hammarstedt, Ann"'

2. Abstract 18221: Interleukin-6 in Patients With HFrEF and the Effect of Dapagliflozin: Insights From DAPA-HF

Author

Docherty, Kieran, Welsh, Paul, Anand, Inder S, Berg, David, de Boer, Rudolf A, Kober, Lars, Kosiborod, Mikhail N, Martinez, Felipe, OMeara, Eileen, Morrow, David, Petrie, Mark, Ponikowski, Piotr, Sabatine, Marc S, Schou, Morten, Sattar, Naveed, Hammarstedt, Ann, Langkilde, Anna Maria, Sjostrand, Mikaela, Solomon, Scott, Jhund, Pardeep S, and McMurray, John J

Published
2023
Full Text
View/download PDF

3. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF

Author

Adamson, Carly, Welsh, Paul, Docherty, Kieran F., de Boer, Rudolf A., Diez, Mirta, Drożdż, Jarosław, Dukát, Andre, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Ljungman, Charlotta E.A., Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Lindholm, Daniel, Hammarstedt, Ann, Boulton, David W., Greasley, Peter J., Langkilde, Anna Maria, Solomon, Scott D., Sattar, Naveed, McMurray, John J.V., and Jhund, Pardeep S.

Published
2023
Full Text
View/download PDF

4. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Yeoh, Su Ern, Docherty, Kieran F., Campbell, Ross T., Jhund, Pardeep S., Hammarstedt, Ann, Heerspink, Hiddo J.L., Jarolim, Petr, Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Solomon, Scott D., Sjöstrand, Mikaela, Bengtsson, Olof, Greasley, Peter J., Sattar, Naveed, Welsh, Paul, Sabatine, Marc S., Morrow, David A., and McMurray, John J.V.

Published
2023
Full Text
View/download PDF

7. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials

Author

McMurray, John J.V., primary, Docherty, Kieran F., additional, de Boer, Rudolf A., additional, Hammarstedt, Ann, additional, Kitzman, Dalane W., additional, Kosiborod, Mikhail N., additional, Maria Langkilde, Anna, additional, Reicher, Barry, additional, Senni, Michele, additional, Shah, Sanjiv J., additional, Wilderäng, Ulrica, additional, Verma, Subodh, additional, and Solomon, Scott D., additional

Published
2023
Full Text
View/download PDF

8. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

Author

Berg, David D., Docherty, Kieran F., Sattar, Naveed, Jarolim, Petr, Welsh, Paul, Jhund, Pardeep S., Anand, Inder S., Chopra, Vijay, de Boer, Rudolf A., Kosiborod, Mikhail N., Nicolau, Jose C., O’Meara, Eileen, Schou, Morten, Hammarstedt, Ann, Langkilde, Anna-Maria, Lindholm, Daniel, Sjöstrand, Mikaela, McMurray, John J.V., Sabatine, Marc S., and Morrow, David A.

Published
2022
Full Text
View/download PDF

10. Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure

Author

Docherty, Kieran F., primary, McDowell, Kirsty, additional, Welsh, Paul, additional, Osmanska, Joanna, additional, Anand, Inder, additional, de Boer, Rudolf A., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, O’Meara, Eileen, additional, Ponikowski, Piotr, additional, Schou, Morten, additional, Berg, David D., additional, Sabatine, Marc S., additional, Morrow, David A., additional, Jarolim, Petr, additional, Hammarstedt, Ann, additional, Sjöstrand, Mikaela, additional, Langkilde, Anna Maria, additional, Solomon, Scott D., additional, Sattar, Naveed, additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

11. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF

Author

Ern Yeoh, Su, primary, Docherty, Kieran F., additional, Campbell, Ross T., additional, Jhund, Pardeep S., additional, Hammarstedt, Ann, additional, Heerspink, Hiddo J.L., additional, Jarolim, Petr, additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Martinez, Felipe A., additional, Ponikowski, Piotr, additional, Solomon, Scott D., additional, Sjöstrand, Mikaela, additional, Bengtsson, Olof, additional, Greasley, Peter J., additional, Sattar, Naveed, additional, Welsh, Paul, additional, Sabatine, Marc S., additional, Morrow, David A., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

13. Iron Deficiency in Heart Failure and Effect of Dapagliflozin

Author

Docherty, Kieran F., Welsh, Paul, Verma, Subodh, De Boer, Rudolf A., O'Meara, Eileen, Bengtsson, Olof, Køber, Lars, Kosiborod, Mikhail N., Hammarstedt, Ann, Langkilde, Anna Maria, Lindholm, Daniel, Little, Dustin J., Sjöstrand, Mikaela, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Schou, Morten, Solomon, Scott D., Sattar, Naveed, Jhund, Pardeep S., McMurray, John J.V., and Cardiovascular Centre (CVC)

Subjects
ferritin, heart failure, Stroke Volume, Iron Deficiencies, sodium-glucose cotransporter 2 inhibitor, anemia, iron, Glucosides, Hepcidins, Physiology (medical), Ferritins, Receptors, Transferrin, Receptors, Erythropoietin, Humans, Transferrins, transferrin, hepcidin, Benzhydryl Compounds, Cardiology and Cardiovascular Medicine, Biomarkers, erythropoiesis
Abstract

Background: Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline. Methods: Iron deficiency was defined as a ferritin level Results: Of the 4744 patients randomized in DAPA-HF, 3009 had ferritin and transferrin saturation measurements available at baseline, and 1314 of these participants (43.7%) were iron deficient. The rate of the primary outcome was higher in patients with iron deficiency (16.6 per 100 person-years) compared with those without (10.4 per 100 person-years; P P -interaction=0.59). Similar findings were observed for cardiovascular death, heart failure hospitalization, and all-cause mortality. Transferrin saturation, ferritin, and hepcidin were reduced and total iron-binding capacity and soluble transferrin receptor increased with dapagliflozin compared with placebo. Conclusions: Iron deficiency was common in DAPA-HF and associated with worse outcomes. Dapagliflozin appeared to increase iron use but improved outcomes, irrespective of iron status at baseline. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03036124.

Published
2022

16. GROWTH DIFFERENTIATION FACTOR-15, CLINICAL OUTCOMES, AND THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION: INSIGHTS FROM THE DAPA-HF TRIAL

Author

Berg, David, primary, Docherty, Kieran F., additional, Talebi, Atefeh, additional, Sattar, Naveed, additional, Jarolim, Petr, additional, Welsh, Paul, additional, Jhund, Pardeep, additional, Anand, Inderjit S., additional, De Boer, Rudolf A., additional, Kosiborod, Mikhail, additional, Kober, Lars, additional, Martinez, Felipe A., additional, O'Meara, Eileen, additional, Ponikowski, Piotr, additional, Schou, Morten, additional, Solomon, Scott D., additional, Hammarstedt, Ann, additional, Langkilde, Anna Maria, additional, McMurray, John J.V., additional, Sabatine, Marc Steven, additional, and Morrow, David A., additional

Published
2023
Full Text
View/download PDF

17. CA125 IN PATIENTS WITH HFREF AND THE EFFECT OF DAPAGLIFLOZIN: INSIGHTS FROM DAPA-HF

Author

McMurray, John J.V., primary, Docherty, Kieran F., additional, Welsh, Paul, additional, Anand, Inderjit S., additional, Berg, David, additional, De Boer, Rudolf A., additional, Jarolim, Petr, additional, Kober, Lars, additional, Kosiborod, Mikhail, additional, Martinez, Felipe A., additional, O'Meara, Eileen, additional, Morrow, David A., additional, Ponikowski, Piotr, additional, Sabatine, Marc Steven, additional, Sattar, Naveed, additional, Schou, Morten, additional, Hammarstedt, Ann, additional, Langkilde, Anna Maria, additional, Sjoestrand, Mikaela, additional, Solomon, Scott D., additional, and Jhund, Pardeep, additional

Published
2023
Full Text
View/download PDF

22. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF

Author

McDowell, Kirsty, Welsh, Paul, Docherty, Kieran F., Morrow, David A., Jhund, Pardeep S., De Boer, Rudolf A., O’Meara, Eileen, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Martinez, Felipe A., Ponikowski, Piotr, Hammarstedt, Ann, Langkilde, Anna Maria, Sjöstrand, Mikaela, Lindholm, Daniel, Solomon, Scott D., Sattar, Naveed, Sabatine, Marc S., McMurray, John J.V., and Cardiovascular Centre (CVC)

Subjects
Male, Heart failure, Sodium–glucose cotransporter 2, FUROSEMIDE, EJECTION FRACTION, Ventricular Dysfunction, Left, Glucosides, Humans, Benzhydryl Compounds, Mortality, Aged, ALLOPURINOL, Sodium-glucose cotransporter 2, GOUT, POST-HOC ANALYSIS, Diabetes, XANTHINE-OXIDASE INHIBITION, Stroke Volume, ASSOCIATION, Middle Aged, CHRONIC HEART-FAILURE, DRUG INTERACTION, HYPERURICEMIA, Female, Cardiology and Cardiovascular Medicine, Uric acid
Abstract

Aims: Blood uric acid (UA) levels are frequently elevated in patients with heart failure and reduced ejection fraction (HFrEF), may lead to gout and are associated with worse outcomes. Reduction in UA is desirable in HFrEF and sodium–glucose cotransporter 2 inhibitors may have this effect. We aimed to examine the association between UA and outcomes, the effect of dapagliflozin according to baseline UA level, and the effect of dapagliflozin on UA in patients with HFrEF in the DAPA-HF trial. Methods and results: The association between UA and the primary composite outcome of cardiovascular death or worsening heart failure, its components, and all-cause mortality was examined using Cox regression analyses among 3119 patients using tertiles of UA, after adjustment for other prognostic variables. Change in UA from baseline over 12 months was also evaluated. Patients in tertile 3 (UA ≥6.8 mg/dl) versus tertile 1 (2), and more often treated with diuretics. Higher UA was associated with a greater risk of the primary outcome (adjusted hazard ratio tertile 3 vs. tertile 1: 1.32, 95% confidence interval [CI] 1.06–1.66; p = 0.01). The risk of heart failure hospitalization and cardiovascular death increased by 7% and 6%, respectively per 1 mg/dl unit increase of UA (p = 0.04 and p = 0.07). Spline analysis revealed a linear increase in risk above a cut-off UA value of 7.09 mg/dl. Compared with placebo, dapagliflozin reduced UA by 0.84 mg/dl (95% CI −0.93 to −0.74) over 12 months (p < 0.001). Dapagliflozin improved outcomes, irrespective of baseline UA concentration. Conclusion: Uric acid remains an independent predictor of worse outcomes in a well-treated contemporary HFrEF population. Compared with placebo, dapagliflozin reduced UA and improved outcomes irrespective of UA concentration.

Published
2022

23. Author response for 'Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND'

Author

null Sen, Taha, null Scholtes, Rosalie, null Greasley, Peter J., null Cherney, David Z. I., null Dekkers, Claire C. J., null Vervloet, Marc, null Danser, Alexander H. J., null Barbour, Sean J., null Karlsson, Cecilia, null Hammarstedt, Ann, null Li, Qiang, null Laverman, Gozewijn D., null Bjornstad, Petter, null van Raalte, Daniel H., and null Heerspink, Hiddo J. L.

Published
2022

24. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND

Author

Sen, Taha, primary, Scholtes, Rosalie, additional, Greasley, Peter J., additional, Cherney, David Z. I., additional, Dekkers, Claire C. J., additional, Vervloet, Marc, additional, Danser, Alexander H. J., additional, Barbour, Sean J., additional, Karlsson, Cecilia, additional, Hammarstedt, Ann, additional, Li, Qiang, additional, Laverman, Gozewijn D., additional, Bjornstad, Petter, additional, van Raalte, Daniel H., additional, and Heerspink, Hiddo J. L., additional

Published
2022
Full Text
View/download PDF

26. FIBROBLAST GROWTH FACTOR-23, CARDIORENAL OUTCOMES, AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN ANALYSIS FROM DECLARE-TIMI 58

Author

Berg, David, primary, Wiviott, Stephen D., additional, Raz, Itamar, additional, Jarolim, Petr, additional, Goodrich, Erica L., additional, Mosenzon, Ofri, additional, Cahn, Avivit, additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John PH, additional, Gause-Nilsson, Ingrid, additional, Hammarstedt, Ann, additional, Oscarsson, Jan, additional, Sabatine, Marc Steven, additional, and Morrow, David A., additional

Published
2022
Full Text
View/download PDF

27. Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures

Author

Movérare-Skrtic, Sofia, Henning, Petra, Liu, Xianwen, Nagano, Kenichi, Saito, Hiroaki, Börjesson, Anna E, Sjögren, Klara, Windahl, Sara H, Farman, Helen, Kindlund, Bert, Engdahl, Cecilia, Koskela, Antti, Zhang, Fu-Ping, Eriksson, Emma E, Zaman, Farasat, Hammarstedt, Ann, Isaksson, Hanna, Bally, Marta, Kassem, Ali, Lindholm, Catharina, Sandberg, Olof, Aspenberg, Per, Sävendahl, Lars, Feng, Jian Q, Tuckermann, Jan, Tuukkanen, Juha, Poutanen, Matti, Baron, Roland, Lerner, Ulf H, Gori, Francesca, and Ohlsson, Claes

Published
2014
Full Text
View/download PDF

28. Abstract 11692: High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial

Author

Berg, David D, primary, Sabatine, Marc S, additional, Sattar, Naveed, additional, Jarolim, Petr, additional, WELSH, Paul, additional, Jhund, Pardeep S, additional, Anand, Inder, additional, De Boer, Rudolf A, additional, Kosiborod, Mikhail, additional, O'Meara, Eileen, additional, Hammarstedt, Ann, additional, Langkilde, Anna Maria, additional, Lindholm, Daniel, additional, Sjöstrand, Mikaela, additional, McMurray, John J, additional, and Morrow, David, additional

Published
2021
Full Text
View/download PDF

31. MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58

Author

Berg, David, primary, Wiviott, Stephen, additional, Goodrich, Erica, additional, Murphy, Sabina, additional, Mosenzon, Ofri, additional, Bhatt, Deepak, additional, Cahn, Avivit, additional, Leiter, Lawrence, additional, McGuire, Darren, additional, Wilding, John, additional, Gause-Nilsson, Ingrid, additional, Hammarstedt, Ann, additional, Karlsson, Cecilia, additional, Johansson, Peter, additional, Langkilde, Anna-Maria, additional, Raz, Itamar, additional, and Sabatine, Marc, additional

Published
2021
Full Text
View/download PDF

32. Inflammation and impaired adipogenesis in hypertrophic obesity in man

Author

Gustafson, Birgit, Gogg, Silvia, Hedjazifar, Shahram, Jenndahl, Lachmi, Hammarstedt, Ann, and Smith, Ulf

Subjects
Obesity -- Health aspects, Insulin resistance -- Development and progression, Inflammation -- Research, Adipose tissues -- Health aspects, Metabolic diseases -- Development and progression, Biological sciences
Abstract

Obesity is associated mainly with adipose cell enlargement in adult man (hypertrophic obesity), whereas the formation of new fat cells (hyperplastic obesity) predominates in the prepubertal age. Adipose cell size, independent of body mass index, is negatively correlated with whole body insulin sensitivity. Here, we review recent findings linking hypertrophic obesity with inflammation and a dysregulated adipose tissue, including local cellular insulin resistance with reduced IRS-1 and GLUT4 protein content. In addition, the number of preadipocytes in the abdominal subcutaneous adipose tissue capable of undergoing differentiation to adipose cells is reduced in hypertrophic obesity. This is likely to promote ectopic lipid accumulation, a well-known finding in these individuals and one that promotes insulin resistance and cardiometabolic risk. We also review recent results showing that TNF[alpha], but not MCP-1, resistin, or IL-6, completely prevents normal adipogenesis in preadipocytes, activates Wnt signaling, and induces a macrophage-like phenotype in the preadipocytes. In fact, activated preadipocytes, rather than macrophages, may completely account for the increased release of chemokines and cytokines by the adipose tissue in obesity. Understanding the molecular mechanisms for the impaired preadipocyte differentiation in the subcutaneous adipose tissue in hypertrophic obesity is a priority since it may lead to new ways of treating obesity and its associated metabolic complications. Wnt signaling; tumor necrosis factor-[alpha]; adipose cells doi: 10.1152/ajpendo.00377.2009.

Published
2009

33. Adult mice are unresponsive to AAV8-Gremlin1 gene therapy targeting the liver

Author

Khatib Shahidi, Roxana, primary, M. Hoffmann, Jenny, additional, Hedjazifar, Shahram, additional, Bonnet, Laurianne, additional, K. Baboota, Ritesh, additional, Heasman, Stephanie, additional, Church, Christopher, additional, Elias, Ivet, additional, Bosch, Fatima, additional, Boucher, Jeremie, additional, Hammarstedt, Ann, additional, and Smith, Ulf, additional

Published
2021
Full Text
View/download PDF

34. A metabolomics based molecular pathway analysis for how the SGLT2-inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

Author

Mulder, Skander, Hammarstedt, Ann, Nagaraj, Sunil B, Nair, Viji, Ju, Wenjun, Hedberg, Jonatan, Greasley, Peter J, Eriksson, Jan W, Oscarsson, Jan, Heerspink, Hiddo J L, Groningen Kidney Center (GKC), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Subjects
PROTOCOL, NEPHROPATHY, sodium-glucose co-transporter-2, RATIONALE, bioinformatics, dapagliflozin, type 2 diabetes, kidney function, CONTRIBUTE, metabolomics
Abstract

Aim: To investigate which metabolic pathways are targeted by the sodium-glucose co-transporter-2 inhibitor dapagliflozin to explore the molecular processes involved in its renal protective effects. Methods: An unbiased mass spectrometry plasma metabolomics assay was performed on baseline and follow-up (week 12) samples from the EFFECT II trial in patients with type 2 diabetes with non-alcoholic fatty liver disease receiving dapagliflozin 10 mg/day (n = 19) or placebo (n = 6). Transcriptomic signatures from tubular compartments were identified from kidney biopsies collected from patients with diabetic kidney disease (DKD) (n = 17) and healthy controls (n = 30) from the European Renal cDNA Biobank. Serum metabolites that significantly changed after 12 weeks of dapagliflozin were mapped to a metabolite-protein interaction network. These proteins were then linked with intra-renal transcripts that were associated with DKD or estimated glomerular filtration rate (eGFR). The impacted metabolites and their protein-coding transcripts were analysed for enriched pathways. Results: Of all measured (n = 812) metabolites, 108 changed (P < 0.05) during dapagliflozin treatment and 74 could be linked to 367 unique proteins/genes. Intra-renal mRNA expression analysis of the genes encoding the metabolite-associated proteins using kidney biopsies resulted in 105 genes that were significantly associated with eGFR in patients with DKD, and 135 genes that were differentially expressed between patients with DKD and controls. The combination of metabolites and transcripts identified four enriched pathways that were affected by dapagliflozin and associated with eGFR: glycine degradation (mitochondrial function), TCA cycle II (energy metabolism), L-carnitine biosynthesis (energy metabolism) and superpathway of citrulline metabolism (nitric oxide synthase and endothelial function). Conclusion: The observed molecular pathways targeted by dapagliflozin and associated with DKD suggest that modifying molecular processes related to energy metabolism, mitochondrial function and endothelial function may contribute to its renal protective effect.

Published
2020

36. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects

Author

Graham, Timothy E.; Qin Yang; Bluher, Matthias, Hammarstedt, Ann; Ciaraldi, Theodore P., Henry, Robert R.; Wason, Christopher J., Oberbach, Andreas; Jansson, Per-Anders, and Smith, Ulf; Kahn, Barbara B.

Subjects
Obesity -- Risk factors, Obesity -- Care and treatment, Insulin resistance -- Health aspects, Protein binding -- Health aspects
Abstract

A study was conducted to determine the serum levels of retinol-binding protein 4, a molecule secreted by adipocytes, correlated with the magnitude of insulin resistance in subjects with obesity, impaired glucose tolerance, or type 2 diabetes and in nonobese, nondiabetic subjects with a strong family history of type 2 diabetes. Levels of adipocytes secreted molecule appear to be elevated in serum before the development of frank diabetes and might be used to identify insulin resistance and associated cardiovascular risk factors.

Published
2006

37. Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Author

Scholtes, Rosalie A., primary, Muskiet, Marcel H.A., additional, van Baar, Michiel J.B., additional, Hesp, Anne C., additional, Greasley, Peter J., additional, Karlsson, Cecilia, additional, Hammarstedt, Ann, additional, Arya, Niki, additional, van Raalte, Daniël H., additional, and Heerspink, Hiddo J.L., additional

Published
2020
Full Text
View/download PDF

39. A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

Author

Mulder, Skander, primary, Hammarstedt, Ann, additional, Nagaraj, Sunil B., additional, Nair, Viji, additional, Ju, Wenjun, additional, Hedberg, Jonatan, additional, Greasley, Peter J., additional, Eriksson, Jan W., additional, Oscarsson, Jan, additional, and Heerspink, Hiddo J. L., additional

Published
2020
Full Text
View/download PDF

47. Single-Nucleotide Polymorphism rs7754840 of CDKAL1 Is Associated with Impaired Insulin Secretion in Nondiabetic Offspring of Type 2 Diabetic Subjects and in a Large Sample of Men with Normal Glucose Tolerance

Author

Stančáková, Alena, Pihlajamäki, Jussi, Kuusisto, Johanna, Stefan, Norbert, Fritsche, Andreas, Häring, Hans, Andreozzi, Francesco, Succurro, Elena, Sesti, Giorgio, Boesgaard, Trine Welløv, Hansen, Torben, Pedersen, Oluf, Jansson, Per Anders, Hammarstedt, Ann, Smith, Ulf, and Laakso, Markku

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results